Edward A. Stadtmauer

Q: What Schools Are Affiliated With Edward A. Stadtmauer

Edward A. Stadtmauer is affiliated with the following schools: Medical College of Wisconsin, University of California, San Diego, University of Pennsylvania

Edward A. Stadtmauer's AcademicInfluence.com Rankings

Engineering

#6979

World Rank

#8336

Historical Rank

Biomedical Engineering

#663

World Rank

#675

Historical Rank

Applied Physics

#2336

World Rank

#2376

Historical Rank

engineering Degrees

Download Badge

Engineering

Edward A. Stadtmauer's Degrees

PhD Biomedical Engineering University of Pennsylvania
Masters Biomedical Engineering University of Pennsylvania
Bachelors Biomedical Engineering University of Pennsylvania

Why Is Edward A. Stadtmauer Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Edward A. Stadtmauer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. (2005) (1965)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. (2007) (1231)
Lenalidomide after stem-cell transplantation for multiple myeloma. (2012) (1028)
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. (2013) (896)
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. (2001) (861)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. (2006) (706)
NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma (2015) (696)
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. (2009) (691)
CRISPR-engineered T cells in patients with refractory cancer (2020) (685)
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. (2012) (608)
Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells (2013) (521)
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. (2007) (515)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. (2015) (487)
bcl-2 Gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia (1993) (458)
A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). (1995) (442)
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence (2005) (422)
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. (2019) (404)
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. (2010) (403)
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. (2004) (390)
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. (2000) (369)
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma (2009) (347)
REDUCTION IN IMMUNOSUPPRESSION AS INITIAL THERAPY FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER: ANALYSIS OF PROGNOSTIC VARIABLES AND LONG-TERM FOLLOW-UP OF 42 ADULT PATIENTS1 (2001) (343)
bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. (1993) (331)
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. (2002) (329)
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer (2005) (306)
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline (2009) (300)
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. (1997) (268)
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials (2007) (259)
Post-transplant lymphoproliferative disorder: a review (2003) (255)
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. (2011) (248)
Combined autophagy and proteasome inhibition (2014) (244)
Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. (2006) (227)
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. (2006) (221)
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. (2009) (220)
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) (2009) (202)
Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. (2001) (200)
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. (2015) (199)
Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. (2012) (191)
Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. (2003) (183)
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study (2008) (180)
Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder ★ (2011) (180)
Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. (1999) (179)
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. (2007) (167)
High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. (1992) (162)
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. (2008) (159)
Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer. (2003) (159)
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. (2011) (156)
A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. (2014) (156)
Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis (2017) (154)
EBV PCR in the Diagnosis and Monitoring of Posttransplant Lymphoproliferative Disorder: Results of a Two‐Arm Prospective Trial (2008) (147)
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. (2019) (145)
Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. (2013) (136)
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multip (2015) (134)
Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. (2015) (133)
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. (2008) (131)
Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. (2011) (128)
Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. (1999) (123)
The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder (2015) (123)
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function (2010) (121)
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. (2018) (116)
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma (2009) (115)
Safety and efficacy of bortezomib in high‐risk and elderly patients with relapsed multiple myeloma (2007) (114)
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma (2008) (111)
Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. (2019) (110)
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. (2019) (109)
A phase 1 study of lucatumumab, a fully human anti‐CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma (2012) (109)
Outcomes of patients with relapsed/refractory diffuse large B‐cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era (2013) (106)
Recommended Guidelines for the Management of Autologous and Allogeneic Bone Marrow Transplantation: A Report from the Eastern Cooperative Oncology Group (ECOG) (1994) (106)
Autologous bone marrow transplant in acute myeloid leukemia in first remission. (1993) (105)
Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells (2013) (104)
Results of a Randomized, Double-Blind Trial of Fluconazole (FLU) vs. Voriconazole (VORI) for the Prevention of Invasive Fungal Infections (IFI) in 600 Allogeneic Blood and Marrow Transplant (BMT) Patients. (2007) (102)
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. (2014) (99)
Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. (2011) (99)
A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia (2009) (98)
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma (2009) (95)
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. (2017) (95)
Rapid Immune Recovery and Graft-versus-Host Disease–like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells (2009) (93)
High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. (2003) (92)
Phase I, multicentre, dose‐escalation trial of monotherapy with milatuzumab (humanized anti‐CD74 monoclonal antibody) in relapsed or refractory multiple myeloma (2013) (91)
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set (2020) (91)
Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104. (2010) (90)
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? (2003) (87)
Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation (2006) (86)
T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. (2019) (86)
Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104 (2010) (85)
Second consensus on medical treatment of metastatic breast cancer. (2007) (83)
Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. (1999) (82)
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single‐arm study (2006) (80)
Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009). (2006) (79)
Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. (2014) (79)
Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). (2010) (76)
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study (2013) (76)
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma (2009) (75)
High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. (2002) (75)
High-dose cytarabine neurotoxicity: MR findings during the acute phase. (1993) (74)
Use of EBV PCR for the Diagnosis and Monitoring of Post‐Transplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Patients (2002) (73)
A predictive model for the detection of tumor lysis syndrome during AML induction therapy (2006) (73)
Changing presentation and management of neutropenic enterocolitis. (1998) (70)
High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. (2011) (70)
B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study (2016) (70)
Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. (2002) (69)
Successful use of the anti‐CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis (2008) (68)
Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. (1996) (67)
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. (2011) (64)
Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial. (2005) (61)
Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia. Eastern Cooperative Oncology Group (E1490). (1999) (61)
Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. (2012) (60)
Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. (2020) (59)
Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM) (2017) (59)
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma (2015) (57)
Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. (2005) (56)
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials (2020) (56)
Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. (2012) (54)
Post-transplant lymphoproliferative disorder after lung transplantation: a review of 35 cases. (2012) (53)
Lenalidomide Plus High-Dose Dexamethasone Provides Improved Overall Survival Compared to High-Dose Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma (MM): Results of 2 Phase III Studies (MM-009, MM-010) and Subgroup Analysis of Patients with Impaired Renal Function. (2006) (51)
Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy (2002) (51)
Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma. (2019) (51)
Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning. (2014) (51)
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. (2018) (50)
Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). (2009) (49)
Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer. (2001) (48)
Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. (2011) (48)
Medical management update: multiple myeloma. (2007) (47)
High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. (2015) (47)
Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM) (2010) (47)
Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients. (2018) (46)
Phase I/II Dose Expansion Of a Multi-Center Trial Of Carfilzomib and Pomalidomide With Dexamethasone (Car-Pom-d) In Patients With Relapsed/Refractory Multiple Myeloma (2013) (46)
High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT (2012) (45)
Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection. (2007) (44)
Association of HLA Polymorphisms with Post‐transplant Lymphoproliferative Disorder in Solid‐Organ Transplant Recipients (2011) (44)
Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). (2020) (44)
Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation. (2001) (43)
Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. (2011) (42)
Posttransplant lymphoproliferative disorder in adult liver transplant recipients: A report of seventeen cases (2007) (42)
Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer. (2000) (42)
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. (2007) (42)
Plasmacytic post‐transplant lymphoproliferative disorder: a case series of nine patients (2013) (40)
Bortezomib-induced tumor lysis syndrome in multiple myeloma. (2006) (38)
Bortezomib vs. dexamethasone in relapsed multiple myeloma: A phase 3 randomized study. (2004) (38)
‘GVHD’: graft-versus-host disease or graft-versus-Hodgkin's disease? an old acronym with new meaning (2003) (36)
Etoposide in leukemia, lymphoma and bone marrow transplantation. (1989) (36)
Classifying ultra-high risk smoldering myeloma (2014) (35)
Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. (2018) (35)
Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail. (2005) (35)
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set (2020) (35)
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma (2012) (35)
Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation. (2000) (34)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+Placebo for Mobilization in Multiple Myeloma (MM) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation. (2007) (34)
Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation (2015) (33)
Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract (2019) (31)
Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen (2011) (31)
Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma (2005) (31)
Danazol treatment of myelodysplastic syndromes (1991) (31)
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma (2016) (30)
Safety and efficacy of upfront plerixafor + G‐CSF versus placebo + G‐CSF for mobilization of CD34+ hematopoietic progenitor cells in patients ≥60 and <60 years of age with non‐Hodgkin's lymphoma or multiple myeloma (2013) (30)
Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma (2017) (30)
A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia (2008) (29)
High-dose chemotherapy and autologous hematopoietic stem cell transplantation for metastatic breast cancer: a therapy whose time has passed (2006) (29)
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma (2009) (29)
Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis (2017) (28)
Bortezomib in relapsed or refractory Waldenström's macroglobulinemia. (2009) (28)
Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide (2016) (28)
Peripheral blood progenitor cell generation and harvesting. (1995) (28)
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR NEUROBLASTOMA: THE CIBMTR EXPERIENCE (2013) (27)
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. (2019) (27)
Inflammatory Cytokine Inhibition with Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease (2010) (27)
Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma. (2015) (27)
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma: Long-term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. (2019) (25)
First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (2020) (25)
Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. (2013) (25)
Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): Preliminary results of the PINNACLE study (2005) (25)
Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an eastern cooperative oncology group trial (E4995) (2005) (25)
Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation (2020) (24)
Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post‐transplant lymphoproliferative disorder * (2005) (24)
Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1b Study (NCT01999335) (2015) (23)
Dose-escalation trial of milatuzumab (humanized anti-CD74 monoclonal antibody) in multiple myeloma. (2016) (23)
Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study. (2004) (23)
Low incidence of hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (mylotarg™, cma-676) (2000) (23)
Autologous stem cell transplantation in first complete remission may not extend progression‐free survival in patients with peripheral T cell lymphomas (2016) (22)
Minimal Residual Disease (MRD) Assessment before and after Autologous Hematopoietic Cell Transplantation (AutoHCT) and Maintenance for Multiple Myeloma (MM): Results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study (2019) (22)
Trimming the fat: obesity and hematopoietic cell transplantation (2013) (22)
Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation (2005) (21)
Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM). (2015) (21)
Bortezomib appears to overcome poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials (2005) (20)
A Phase 1 Dose Escalation Study of a Fully Human, Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12) in Patients with Relapsed and Refractory Multiple Myeloma. (2006) (20)
Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer (2003) (20)
Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. (2019) (19)
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia (2022) (18)
Modeling the risk of progression in smoldering multiple myeloma. (2014) (18)
Chimeric Antigen Receptor T Cells in Myeloma. (2016) (18)
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed myeloma (2005) (18)
Hematologic Profiles in the Phase 3 APEX Trial. (2005) (18)
Blood and marrow transplant clinical trials network state of the Science Symposium 2014. (2015) (18)
Post‐transplant outcomes of induction therapy for myeloma: Thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high‐dose melphalan with autologous stem cell support (2007) (18)
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. (2019) (18)
Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma (2017) (17)
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. (2022) (17)
Trisomy 8 in an allogeneic stem cell transplant recipient representative of a donor‐derived constitutional abnormality (2008) (17)
Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma (2018) (17)
Clinical Outcomes of Patients with Desmoplastic Small Round Cell Tumor of the Peritoneum Undergoing Autologous HCT: a CIBMTR Retrospective Analysis (2012) (17)
Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia. (2002) (16)
Pembrolizumab in Combination with Pomalidomide and Dexamethasone (PEMBRO/POM/DEX) for Pomalidomide Exposed Relapsed or Refractory Multiple Myeloma (2016) (16)
The evolving role of plerixafor in hematopoietic progenitor cell mobilization (2013) (16)
Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination (1999) (16)
Comparison of high doses of total body irradiation in myeloablative conditioning prior to hematopoietic cell transplantation. (2019) (16)
Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) (2010) (16)
Multiple myeloma, 2004--one or two transplants? (2003) (16)
Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma. (2006) (16)
Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy (2020) (15)
PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells (2018) (15)
Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation (2005) (15)
Longer Duration of Treatment and Maintenance of Best Response with Lenalidomide and Dexamethasone Prolongs Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma (2008) (15)
Cellular and vaccine immunotherapy for multiple myeloma. (2016) (14)
Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma. (2015) (14)
Randomized Phase III Trial of 131iodine-Tositumomab (Bexxar)/Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) Vs. Rituximab/BEAM and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL): No Difference in Progression-Free (PFS) or Overall Survival (OS) (2011) (14)
Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance (2012) (14)
Adoptive Transfer of Gene-Modified T-Cells Engineered to Express High-Affinity TCRs for Cancer-Testis Antigens (CTAs) NY-ESO-1 or Lage-1, in MM Patients Post Auto-SCT (2012) (14)
Risk of invasive fungal infections in patients with high‐risk MDS and AML receiving hypomethylating agents (2020) (14)
Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice (2021) (13)
Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene (2007) (13)
Utility of single versus tandem autotransplants for advanced testes/germ cell cancer: a center for international blood and marrow transplant research (CIBMTR) analysis. (2007) (13)
Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events. (2009) (13)
Anti-CD 19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma (2018) (13)
Consensus on Medical Treatment of Metastatic Breast Cancer (2003) (13)
The presence of amyloid in abdominal and oral mucosal tissues in patients initially diagnosed with multiple myeloma: a pilot study. (2011) (13)
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT) (2022) (12)
Fluoroquinolone Prophylaxis Is Highly Effective for the Prevention of Central Line-Associated Bloodstream Infections in Autologous Stem Cell Transplant Patients. (2019) (12)
A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma. (1997) (12)
Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma (2019) (12)
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD 3 / CD 28 costimulation (2006) (12)
Summary of the Third Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. (2020) (11)
Chronic Lymphocytic Leukemia: New Concepts and Emerging Therapies (2009) (11)
Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs (2010) (11)
A dramatic story of hope and reality. (2008) (11)
Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy. (1999) (10)
Poor-prognosis germ cell tumors: we have not yet crossed the finish line. (2007) (10)
R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma. (2015) (10)
High-dose chemotherapy with autologous stem cell support for breast cancer. (1992) (10)
Hematologic Malignancies: Plasma Cell Disorders. (2017) (10)
The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies (2016) (10)
Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen (2016) (10)
A pilot trial of quantitative Epstein–Barr virus polymerase chain reaction in patients undergoing treatment for their malignancy: potential use of Epstein–Barr virus polymerase chain reaction in multiple cancer types (2015) (9)
First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma. (2019) (9)
Combined radiation and chemotherapy in posttransplant lymphoproliferative disorder (1998) (9)
Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM) (2018) (9)
12 Months Report from a Phase 3 Study of Plerixafor+G-CSF Vs. Placebo+G-CSF for Mobilization of Hematopoietic Stem Cell for Autologous Transplant in Patients with Multiple Myeloma (2008) (9)
Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial (2021) (9)
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia (2002) (9)
Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. (2021) (8)
Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation (2017) (8)
Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. (2014) (8)
Analysis of Varicella Zoster Virus Reactivation among Bortezomib-Treated Patients in the APEX Study. (2006) (8)
Autologous bone marrow transplantation. A review of the principles and complications. (1993) (8)
A Phase I Dose Escalation Study of the mTOR Inhibitor Sirolimus and MEC Chemotherapy Targeting Signal Transduction in Leukemic Stem Cells for Acute Myeloid Leukemia. (2006) (8)
Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody. (2003) (8)
Genetically engineered NY-ESO-1 specific T cells in HLA-A201+ patients with advanced cancers. (2015) (8)
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. (2022) (8)
The Impact of Rituximab Resistance on Overall Survival Rate in Low-Grade Follicular Lymphoma (2008) (7)
Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma. (2022) (7)
Cerebral spinal fluid involvement by Hodgkin's disease diagnosed by CSF cytology and immunocytochemistry (1999) (7)
A Schematic Approach to Preexisting Sinus Disease for the Immunocompromised Individual (1998) (7)
Bone marrow purging with oligodeoxynucleotides [letter; comment] (1996) (7)
Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial. (2004) (7)
High-Dose Chemotherapy and Stem Cell Support for Breast Cancer (2002) (7)
Acute cholecystitis is a common complication after allogeneic stem cell transplantation and is associated with the use of total parenteral nutrition. (2015) (7)
Nutrition-Related Outcomes for Autologous Stem Cell Transplantation Patients. (2019) (7)
First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma (2008) (7)
Cellular immunotherapy for plasma cell myeloma (2013) (7)
Progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem-cell transplantation: changing the natural history with monoclonal antibody therapy. (2000) (7)
Expanded Access Program (EAP) for Lenalidomide (Revlimid®) Plus Dexamethasone in over 1400 Subjects with Relapsed or Refractory Multiple Myeloma. (2006) (7)
Melphalan/total body irradiation-conditioned myeloablative allogeneic hematopoietic cell transplantation for patients with primary plasma cell leukemia. (2014) (7)
Immunoglobulin Free Light Chain (FLC) and Heavy Chain/Light Chain (HLC) Assays – Comparison with Electrophoretic Responses in Multiple Myeloma (MM) (2011) (7)
Lenalidomide and stem cell collection in patients with multiple myeloma (2008) (6)
Reduction of Immunosuppression as Initial Therapy for Post-Transplantation Lymphoproliferative Disorder: Analysis of Efficacy, Safety and Prognostic Factors. (2009) (6)
Preliminary Results of a Phase 2 Study of PD 0332991 in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma (2011) (6)
Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation. (2014) (6)
Bortezomib is active in Waldenstrom's Macroglobulinemia (WM)-Results of a National Cancer Institute of Canada (NCIC) phase II study in previously untreated or treated WM. (2006) (6)
Carfilzomib-associated cardiovascular adverse events: A systematic review and meta-analysis. (2017) (6)
Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma (2019) (6)
Detection of Bone Marrow Breast Carcinoma Metastasis Using Multiparameter Flow Cytometry (1993) (6)
Lenalidomide (Len) in combination with dexamethasone (Dex) is more effective than Dex alone at first relapse and provides better outcomes when used early rather than as later salvage therapy in relapsed multiple myeloma (MM). (2006) (6)
Reactive lymphohistiocytosis with recurrence in the optic chiasm. (1991) (6)
Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation (2015) (5)
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. (2007) (5)
Plerixafor and G-CSF Versus Cyclophosphamide and G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma. (2009) (5)
Femtomolar SARS-CoV-2 Antigen Detection Using the Microbubbling Digital Assay with Smartphone Readout Enables Antigen Burden Quantitation and Tracking (2021) (5)
NF-kappaB, IL-6 and myeloma cell growth: Making the connection (2004) (5)
Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograft products from multiple myeloma patients (2000) (5)
Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancer. (1997) (5)
4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation in non-Hodgkin's lymphoma patients at high risk of bone marrow involvement. (1996) (5)
Oral Vancomycin Is Highly Effective in Preventing Clostridium Difficile infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients (2016) (5)
Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment (2016) (5)
Concurrent Administration of Interferon Alfa-2b and Beta-1a (2003) (5)
Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia (2021) (5)
Relationship between Quality of Response to Bortezomib (btz) and Clinical Benefit in Multiple Myeloma (MM) in the APEX and SUMMIT Studies. (2006) (5)
Phase I/II Multicenter Clinical Trial of Lenalidomide Maintenance After Allogeneic Hematopoietic Cell Transplant (alloHCT) in Patients with High Risk (HR) Multiple Myeloma (MM) (2013) (5)
Do simultaneous bilateral tunneled infusion catheters in patients undergoing bone marrow transplantation increase catheter-related complications? (2004) (5)
Tailoring initial treatment for newly diagnosed, transplantation-eligible multiple myeloma. (2010) (5)
Combination Immunotherapy After ASCT for Multiple Myeloma (MM) Using MAGE-A3/Poly-ICLC Immunizations Followed by Vaccine-Primed and Activated Autologous T-Cells (2012) (5)
Treatment of primary resistant or relapsed multiple myeloma with high-dose chemoradiotherapy, hematopoietic stem cell rescue, and granulocyte-macrophage colony-stimulating factor. (2000) (4)
BMT CTN State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. (2021) (4)
Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Following Autologous Hematopoietic Stem Cell Transplant in Patients with Non-Hodgkin’s Lymphoma and Multiple Myeloma. (2008) (4)
Similar 1 Year Survival of Patients Receiving Plerixafor (Mozobil*®) Plus G-CSF Versus Placebo Plus G-CSF Mobilized Autologous Grafts: Results From Two Phase 3 Randomized Trials in Patients with NHL or MM Undergoing Autologous Transplantation After Front-Line or Rescue Mobilization. (2009) (4)
Association between mobilization regimen and PFS after auto-SCT for multiple myeloma (2014) (4)
Effect of Pharmacokinetic Variability on the Toxicity and Efficacy of High-Dose Melphalan for Multiple Myeloma (2010) (4)
Extended CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis – a Phase II Study (2014) (4)
A Phase I Study of Hydroxychloroquine with Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients with Relapsed or Refractory Multiple Myeloma (2014) (4)
Clofarabine Busulfan Conditioning Improves Outcomes in Patients with Active Acute Myelogenous Leukemia Undergoing Allogeneic Stem Cell Transplant (2014) (4)
One-Year Safety and Immunogenicity of Two Formulations of an Adjuvanted Varicella-Zoster Virus (VZV) Subunit Candidate Vaccine in Adult Autologous Hematopoietic Cell Transplant (HCT) Recipients (2013) (4)
Homocysteine and prothrombin fragment 1+2 levels in patients with veno-occlusive disease after stem cell transplantation. (2003) (4)
The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. (2021) (4)
A Multicenter Phase II Study of Combination Treatment with Melphalan, Arsenic Trioxide and Vitamin C (MAC) for Patients with Relapsed or Refractory Multiple Myeloma. (2005) (4)
Survival Analysis from the CALGB Study of Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation Adjusted for Crossover (Alliance 100104) (2018) (4)
A Randomized Phase II Trial of Idiotype Vaccination and Adoptive Autologous T-Cell Transfer in Multiple Myeloma patients. (2021) (4)
Phase I/IIa Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells Administered Following Autologous Stem Cell Transplant in HLA-a*02+ Patients with Advanced Multiple Myeloma: Long Term Follow-up (NCT01352286) (2017) (4)
Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study (2017) (4)
Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Preliminary Results of a Phase 1/2 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Relapsed or Refractory Myeloma (2008) (4)
Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist – Final Results of a Phase I/II Study (2011) (4)
CAR T-Cell Therapy: On the Verge of Breakthrough in Many Hematologic Malignancies (2017) (3)
Non-infectious pulmonary toxicity after allogeneic hematopoietic cell transplantation. (2022) (3)
Plerixafor (Mozobi ® )Plus G-CSF Is More Effective Than Placebo Plus G-CSF in Mobilizing CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma Who Have Low (<20 cells/μl) Peripheral Blood CD34+ Cell Count. (2009) (3)
Adoptive Transfer of Ex Vivo Costimulated Autologous T-Cells in Conjunction with Pneumococcal Conjugate Vaccine Immunizations Accelerates Post-Transplant T-Cell Recovery after Autotransplantation for Myeloma: Results of a Randomized Study. (2004) (3)
Guidelines for prophylactic platelet transfusions: need for a concurrent outcomes management system. (1992) (3)
Enhancing Graft-vs-Tumor (GVT) Activity of Donor Leukocyte Infusions by Ex-Vivo Expansion and Activation with CD3/CD28 Co-Stimulation. (2004) (3)
Adoptive transfer of ex vivo costimulated autologous T-cells after autotransplantation for myeloma (MM)accelerates post-transplant T-cell recovery (2004) (3)
Impact of prior autologous stem cell transplant (ASCT) in patients receiving bortezomib or dexamethasone for relapsed/refractory multiple myeloma in the APEX trial. (2006) (3)
Expanded Comorbidity Definitions Improve Applicability of the Hematopoietic Stem Cell Transplantation-Comorbidity Index for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation (2020) (3)
Analysis of Second Primary Malignancies (SPMs) in CALGB (Alliance)/ECOG/BMT CTN 100104 (2015) (3)
Tocilizumab Is Highly Active for Severe Steroid-Refractory Acute Graft-Versus-Host Disease of the Gastrointestinal Tract (2016) (3)
Bone marrow purging with oligodeoxynucleotides. (1996) (3)
Thalidomide and Dexamethasone Induction Therapy Is Associated with Superior Progression-Free Survival after Autotransplant for Myeloma. (2005) (3)
Source of donor stem cells impacts incidence of bleeding and platelet and RBC transfusion requirements during stem cell transplantation (SCT): results of the phase III sprint trial of intercept pathogen inactivated platelets (2004) (3)
Hematologic Malignancies: Plasma Cell Disorders. (2017) (3)
Interleukin-6 174G3C Polymorphism Is Associated with Improved Outcome in High-Risk Breast Cancer (2003) (3)
HLA-Identical Sibling-Matched, CD34+ Selected, T Cell Depleted Peripheral Blood Stem Cells Following Myeloablative Conditioning for First or Second Remission Acute Myeloid Leukemia (AML): Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303. (2009) (3)
Mobilization with Plerixafor (Mozobil ®)Plus G-CSF Results in Superior Day 1 Collection of CD34+ Cells Compared to Placebo Plus G-CSF: Results From Two Randomized Placebo-Controlled Trials in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma. (2009) (3)
Histamine dihydrochloride and interleukin-2 in the treatment of acute myeloid leukemia. (2002) (3)
Autologous bone marrow transplantation with in vitro chemotherapy purge in first remission of acute myeloid leukemia. (1992) (3)
Circulating Multiple Myeloma Cells (CMMCs): A Novel Method for Detection and Molecular Characterization of Peripheral Blood Plasma Cells in Multiple Myeloma Precursor States (2014) (3)
Durable Responses with Bortezomib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL): Updated Time-to-Event Analyses of the Multicenter PINNACLE Study. (2007) (3)
Femtomolar SARS-CoV-2 Antigen Detection Using the Microbubbling Digital Assay with Smartphone Readout Enables Antigen Burden Quantitation and Dynamics Tracking (2021) (3)
Unrelated donors are associated with improved relapse‐free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation (2016) (3)
MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial. (2021) (3)
Pupil-involving third nerve palsy as a manifestation of anti-myelin-associated glycoprotein neuropathy. (2011) (2)
Leukemic gingival infiltrate as an indicator of chemotherapeutic failure following monoclonal antibody therapy: a case report. (2003) (2)
Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Long-Term Follow up (2019) (2)
Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells (2023) (2)
Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment and Length of Hospitalization in Myeloablative Allogeneic Hematopoietic Transplantation (2019) (2)
A review of the principles and complications (1993) (2)
CAR T cell therapy for multiple myeloma: What have we learned? (2022) (2)
Comparable outcomes in CLL patients treated with reduced-dose ibrutinib: Results from a multi-center study. (2016) (2)
High Dose Chemotherapy and Autologous Stem Cell Transplantation for Metastatic Breast Cancer: Is there a Place? (2003) (2)
Adoptive transfer of gene-modified T-cells engineered to express high-affinity tcr's for cancer-testis antigens NY-ESO-1 or lage-1, in multiple myeloma (MM) patients post autologous hematopoietic stem cell transplant (ASCT) (2013) (2)
A Phase 1 Trial of Fluphenazine HCl (Fz), a Serotonin Antagonist, in Relapsed and Refractory Multiple Myeloma (2008) (2)
Conflicts of interest, authorship, and disclosures in industry-related scientific publications. (2010) (2)
Anti-BCMA/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy. (2022) (2)
Comparison of lenalidomide plus dexamethasone therapy used at first relapse versus later salvage therapy in relapsed or refractory multiple myeloma patients. (2009) (2)
Reproducibility of the Penn predictive score of tumor lysis syndrome (PPS-TLS) in acute myelogenous leukemia (AML). (2006) (2)
Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration. (2013) (2)
Myeloid derived suppressor cells (MDSCS) reduce the manufacturing feasibilty of gene modified T cells. (2019) (2)
Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI (2016) (2)
Autologous Stem Cell Transplantation in First Complete Remission May Not Extend Progression Free Survival in Patients with ALK-Negative Peripheral T Cell Lymphoma (2015) (2)
CALGB/ECOG 100104 (Alliance) study: Lenalidomide (LEN) vs placebo (PBO) maintenance (maint) after stem cell transplant (SCT) for patients (pts) with multiple myeloma—Overall survival (OS) and progression-free survival (PFS) adjusted for treatment (tx) crossover (XO). (2017) (2)
PS1375 UPDATED SAFETY AND EFFICACY FROM A PHASE 2 STUDY OF VENETOCLAX PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (2019) (2)
A Single-Center Retrospective Comparison of Post-Transplant Outcomes in Patients Receiving VRD Vs. VD Vs. RD As Initial Therapy Prior to ASCT for Newly Diagnosed Multiple Myeloma (MM) (2012) (2)
Continuous Infusion Cyclophosphamide as Salvage Therapy for Relapsed or Refractory Multiple Myeloma. (2009) (2)
Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay. (2021) (2)
Differential use of the hematopoietic cell transplantation-comorbidity index among adult and pediatric transplant physicians (2022) (2)
Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival. (2007) (2)
Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis in Myeloablative Allogeneic Hematopoietic Transplantation Shortens the Duration of Mucositis and Hospitalization (2018) (2)
First Report of the Prophylactic Administration of Ex Vivo Co-Stimulated Donor Lymphocyte Infusion (DLI) from Related and Unrelated Donors after Reduced Intensity Conditioning for High Risk Hematologic Malignancies (2008) (2)
Prevention of Graft-Versus-Host Disease by Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist (2010) (2)
A phase 2 study of single-agent carﬁlzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma (2012) (2)
Melphalan desensitization following immediate hypersensitivity in a patient undergoing conditioning for autologous hematopoietic cell transplantation. (2016) (2)
Pharmacokinetics, Dosimetry, and Initial Therapeutic Results with 131I- and lllIn-/9~ Humanized LL2 Anti-CD22 Monoclonal Antibody in Patients with Relapsed, Refractory Non-Hodgkin's Lymphoma I (2007) (2)
Fried’s Frailty Phenotype Predicts Overall Survival for Older Hematopoietic Cell Transplantation Recipients (2021) (2)
P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (2022) (2)
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma (2022) (2)
Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Final Results of a Phase 1 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Patients with Relapsed or Refractory Myeloma (2011) (2)
Is There a Role for ASCT in Patients with Desmoplastic Small Round Cell Tumor of the Peritoneum (2011) (2)
4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation of relapsed, responding non-Hodgkin's lymphoma with granulocyte colony stimulating factor support results in reliable hematopoietic recovery. (1994) (1)
Effect of rituximab (R) on clinical outcomes after autologous stem cell transplantation (ASCT) in pts with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (2007) (1)
What did we learn in 2010 from the phase III trials? Is maintenance therapy the new standard for myeloma? (2011) (1)
Pharmacokinetics and Safety of Once-Daily Intravenous Busulfan with Bortezomib in Patients with Relapsed Multiple Myeloma Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation (2012) (1)
Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society COVID-19 Dataset (2020) (1)
Feasibility, Safety and Efficacy of Maraviroc, a CCR5 Antagonist, in Graft-Versus-Host Disease Prevention After Reduced intensity Conditioned (RIC) Allogeneic Stem Cell Transplant (SCT): a Phase I/II Study (2011) (1)
Next-generation sequencing to identify mutations that may predict outcome after allogeneic stem cell transplantation for AML. (2014) (1)
Receipt of Maintenance Therapy Is Most Predictive of Survival in Older Acute Lymphoblastic Leukemia Patients Treated with Intensive Induction Chemotherapy Regimens. (2012) (1)
Outcomes in patients with relapsed/refractory Hodgkin lymphoma (RR-HL) with progression after autologous stem cell transplantation in the current era of novel therapeutics. (2016) (1)
Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide (2022) (1)
Autologous aGVHD Associated with Infusion of T-Cells with Engineered Specificity for NY-ESO-1 and LAGE-1 Following High-Dose Melphalan and ASCT in Patients with Multiple Myeloma (2013) (1)
Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle (2010) (1)
Anti-CD33 calicheamicin immunoconjugate therapy of acute myeloid leukemia (2004) (1)
A Prospective Multicenter Phase II Trial of Pentostatin in Adult Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease (cGvHD): A Cancer and Leukemia Group B/Eastern Cooperative Oncology Group Study. (2009) (1)
448 Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study (2021) (1)
Effect of Body Composition and Renal Function on the Pharmacokinetics of High-Dose Melphalan for Multiple Myeloma (2012) (1)
Extended Course of Maraviroc, a CCR5 Antagonist, Is Safe and Effective in Graft-Versus-Host Disease Prophylaxis. Final Results of a Phase II Study (2017) (1)
Association of higher total nucleated cell dose with improved survival in patients receiving donor lymphocyte infusion after allogeneic stem cell transplantation. (2015) (1)
Multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic transplantation for high-risk multiple myeloma: Results of the BMT CTN 1302 Trial. (2022) (1)
Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing (2018) (1)
Pegfilgrastim versus filgrastim to accelerate hematopoietic recovery after high-dose melphalan and autologous hematopoietic stem cell transplantation (ASCT) for multiple myeloma (2005) (1)
Effect of malnutrition-driven nutritional support protocol on clinical outcomes in autologous stem cell transplantation patients (2020) (1)
Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. (2018) (1)
Characterization of autologous T cells engineered to express NY-ESO-1 TCR with multiplexed CRISPR/Cas9 editing (NYCE T Cells) (2020) (1)
The Optimal Timing for Stem Cell Collection After Induction Therapy for Patients with Multiple Myeloma (2010) (1)
Rapid T Cell Recovery and Possible Auto-GVHD Following Adoptive Transfer of Ex-Vivo Costimulated Autologous T Cells at Day +2 Post-Transplant. (2007) (1)
B‐cell maturation antigen chimeric antigen receptor T‐cell re‐expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor‐based combination therapy (2021) (1)
Characterization of Pericarditis Following Allogeneic Hematopoietic Cell Transplant. (2021) (1)
CD8 Cell Dose in Peripheral Blood Stem-Cell Grafts Correlates with Relapse and Survival after Reduced Intensity Allogeneic Stem-Cell Transplantation (2014) (1)
Co-stimulated autologous T-cell infusion after autologous stem cell transplantation (SCT) for myeloma accelerates lymphocyte recovery and augments response to pneumoccal vaccine: Results of a randomized trial (2005) (1)
Prophylactic Administration Of Ex VIVO Co-Stimulated Donor Lymphocyte Infusion (DLI) From Related And Unrelated Donors After Reduced Intensity Conditioning For High Risk Hematologic Malignancies (2009) (1)
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Breast Cancer (2002) (1)
EBV-negative post-transplant lymphoproliferative disorder: Clinical characteristics, response to therapy, and survival. (2013) (1)
Engineered T-Cells Expressing An HLA-Restricted Affinity-Enhanced TCR In Advanced Multiple Myeloma Patients Post Auto-SCT Engraft and Are Associated With Encouraging Post Auto-SCT Responses (2013) (1)
Clofarabine and busulfan myeloablative conditioning in allogeneic hematopoietic cell transplant for patients with active myeloid malignancies. (2022) (1)
Outcome of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Cytarabine Monotherapy (2015) (1)
A Survival Benefit for Reduced Intensity Allogeneic Transplants from Young Unrelated Donors Compared to Older Sibling Donors Depends on the Graft CD8 T-Cell Content (2015) (1)
Outcomes of Patients with Refractory/Relapsed Diffuse Large B-Cell Lymphoma Who Progress After Autologous Stem Cell Transplantation in the Rituximab Era. (2012) (1)
Effect of Obesity and Renal Insufficiency On Toxicity of High-Dose Melphalan for Multiple Myeloma. (2009) (1)
Stem Cell Mobilization With Plerixafor + G-CSF In Comparison To Cyclophosphamide + G-CSF and Time-To-Progression After Autologous Stem Cell Transplantation For Multiple Myeloma (2013) (1)
Final Report of Safety and Efficacy From a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation. (2012) (1)
High-dose therapy and growth factor mobilized peripheral blood progenitor cell support for responding patients with metastatic breast cancer. (1994) (1)
Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT (2013) (1)
Defining The Optimal Threshold Of Peripheral Blood (PB) CD34+Cells To Initiate Apheresis In Patients With NHL Undergoing Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) After G-CSF Mobilization (2010) (1)
Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation? (2022) (1)
Pegfilgrastim Versus Filgrastim To Accelerate Hematopoietic Recovery after High Dose Melphalan and Autologous Hematopoietic Stem Cell Transplant (ASCT) for Multiple Myeloma. (2004) (1)
Process for Pathogen Inactivation: The SPRINT Trial Therapeutic Efficacy and Safety of Platelets Treated with a Photochemical (2012) (1)
Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation. (2022) (1)
Prognostic Value of FDG-PET in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. (2005) (1)
Assessing financial toxicity in insured patients with multiple myeloma. (2015) (1)
A Predictive Model for Tumor Lysis Syndrome in Acute Myelogenous Leukemia. (2004) (1)
Post-transplant lymphoproliferative disorder in adult lung transplant recipients: A report on twenty-seven patients (2008) (1)
A phase II, multicenter, randomized, double-blind, placebo-controlled trial of the safety and efficacy of velafermin (CG53135-05) administered intravenously as a single dose for the prevention of oral mucositis in patients receiving autologous hematopoietic stem cell transplant (AHSCT) (2006) (1)
Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors. (2016) (1)
Prospective Study of Cardiac Events during Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma (2017) (1)
Progressive multifocal leukoencephalopathy in multiple myeloma (2022) (1)
Proteasome inhibitor associated cardiovascular adverse events: A real-world claims based study. (2019) (1)
Abstract 4701: NY-ESO T cells administered post ASCT for MM exhibit extended functionality without exhaustion in a natural pattern of effector and memory programming (2015) (1)
Overall Survival (OS) and Progression-Free Survival (PFS) Adjusted for Treatment Crossover in the CALGB/ECOG 100104 (Alliance) Study of Lenalidomide (LEN) Versus Placebo (PBO) Maintenance After Stem Cell Transplant (SCT) for Patients With Newly Diagnosed Multiple Myeloma (2017) (1)
Effect of Obesity on Outcomes after Alternative Donor Allogeneic Hematopoietic Stem Cell Transplant (alloHCT) (2021) (0)
Real World Effectiveness of "7 + 3" Intensive Chemotherapy Vs Venetoclax and Hypomethylating Agent for Initial Therapy in Adult Acute Myeloid Leukemia (2022) (0)
Acute Cholecystitis Occurs More Commonly Than Expected Following Allogeneic Hematopoietic Stem Cell Transplantation and Is Ineffectively Diagnosed Using Abdominal Ultrasound (2013) (0)
Impact Of Autologous Stem Cell Transplantation In Older Patients With Mantle Cell Lymphoma (2013) (0)
What Is the Role of Autologous Stem Cell Transplantation for Leukemia (2000) (0)
CLINICAL Cardiovascular toxicity and titin cross-reactivity of af ﬁ nity-enhanced T cells in myeloma and melanoma (2013) (0)
OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (2021) (0)
Expanded Comorbidity Definitions Improve Application of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for Children and Young Adults with Non-Malignant Diseases Receiving Allogeneic Hematopoietic Cell Transplantation (2020) (0)
A Comparison of Two Induction Regimens for Older Patients with Acute Lymphoblastic Leukemia: Daunorubicin, Vincristine and Prednisone (DVP) is Worth Considering (2010) (0)
US Cooperative Group Trials (2009) (0)
ex-vivo via CD3/CD28 co-stimulation A phase I trial of donor lymphocyte infusions expanded and activated (2012) (0)
Efficacy, safety, and cost of mobilization strategies in multiple myeloma: A prospective observational study. (2023) (0)
Prolonged Survival Can be Achieved By Primary Plasma Cell Leukemia and Multiply-Refractory Multiple Myeloma Patients with Responding Disease Prior to Melphalan/Total Body Irradiation-Conditioned Myeloablative Allogeneic Hematopoietic Cell Transplantation (2014) (0)
Acute myeloid leukaemia Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease (2002) (0)
Breast tumor cell contamination of hematopoietic stem cell collections. (2001) (0)
Proteasome inhibition for treatment of multiple myeloma: clinical update. (2004) (0)
Prolongation of Progression Free Survival In Mantle Cell Lymphoma After RHCVAD: ASCT Consolidation or Rituximab Maintenance (2010) (0)
Allogeneic Transplantation for the Treatment of Multiple Myeloma (2010) (0)
Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy for Relapsed Multiple Myeloma. (2005) (0)
High-Throughput Sequencing of Antibody Genes Successfully Identifies Clonal Ig Rearrangements in Multiple Myeloma Patients (2014) (0)
Comparison of bortezomib- and lenalidomide-based therapies for the treatment of primary (AL) amyloidosis. (2010) (0)
Age and Response after Autologous Stem Cell Transplantation (ASCT) Define a Group of Long-Term Event-Free Survivors among Patients (Pts) with Low-Grade Follicular Lymphoma (FL): A Single Institution Experience. (2004) (0)
A two-arm prospective trial evaluating the ability of EBV PCR to diagnose and monitor posttransplant lymphoproliferative disorder (2007) (0)
A Prospective Clinical Trial of a Novel Epstein-Barr Virus (EBV) PCR Panel in Patients with EBV Associated Malignancies. (2007) (0)
Non-Myeloablative Conditioning with Allogeneic Progenitor Cell Transplantation for Relapsed Hodgkin’s Lymphoma: High Response Rate Despite Prior Chemoresistance. (2004) (0)
The NSG-hIL6 Mouse As a Novel Murine Patient Derived Xenograft Model of Plasma Cell Dyscrasias for Study of Disease Biology and Therapeutic Development (2022) (0)
Myeloablative vs non-myeloablative conditioning with allogeneic stem cell transplantation for high risk non-Hodgkin’s lymphoma: Similar outcomes despite differences in disease risk (2005) (0)
Oral Abstracts (2022) (0)
Clofarabine and Busulfan Conditioning and Allogeneic Stem Cell Transplantion for Patients with Active Myeloid Malignancies (2021) (0)
Outcomes of Myeloablative Hematopoietic Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia with Relapsed or Refractory Disease (2010) (0)
Utility of Prophylactic Autologous Stem Cell Collection for Patients with Acute Myeloid Leukemia in First Remission. (2004) (0)
Leukaemia and myeloma LEUKAEMIA AND MYELOMA | 424OI The efficacy and safety of gemtuzumab ozogamicin (CMA-676) in patients with acute myeloid leukemia in first relapse (2005) (0)
Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study (2020) (0)
Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens (2013) (0)
Long Term Follow-Up of 4-Hydroperoxycyclophosphamide Purged Autologous Bone Marrow Transplantation in Non-Hodgkin’s Lymphoma Patients with High Risk of Bone Marrow Involvement. (2004) (0)
Phase 2 Study of Belantamab Mafodotin As Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission (2022) (0)
Risk-stratified treatment of patients with metastatic germ cell tumor with progression after first-line therapy. (2015) (0)
Phase 2 study of venetoclax plus car ﬁ lzomib and dexamethasone in patients with relapsed/refractory multiple myeloma (2021) (0)
Posttransplant Lymphoproliferative Disorder in Liver Transplant Recipients: A Report of Seventeen Cases. (2005) (0)
Outpatient autologous stem cell transplants for selected patients with myeloma: Morbidity, mortality, and duration of hospitalization (2007) (0)
Abstract 3430: Toxicity and long-term outcomes of elderly patients with refractory or relapsed diffuse large B cell lymphoma undergoing autologous stem cell transplantation (2015) (0)
The Incidence of Amyloid Deposition in Abdominal and Oral Mucosal Tissue in Patients Initially Diagnosed with Multiple Myeloma (2008) (0)
Pharmacokinetics and Safety of a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation (2011) (0)
Results of a Phase I/II Randomized Immunotherapy Trial Testing Adoptive Transfer of Co-Stimulated Autologous T Cells and Pneumococcal Conjugate Vaccine (PCV) Immunization after Autotransplantation for Myeloma (MM). (2004) (0)
511. Enhanced-Affinity NY-ESO-1-Specific T Cells Exhibit Extended Functionality without Exhaustion in a Pattern of Effector and Memory Programming in Multiple Cancer Indications (2015) (0)
Outcomes of Salvage Second Autologous Stem Cell Transplantation for Relapsed/Refractory Multiple Myeloma in the Era of Modern Therapy (2017) (0)
Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy. (2021) (0)
Abstract IA01: Single cell analysis of CRISPR T cells (2020) (0)
Serum LDH predicts response rate, response duration, and survival of patients (pts) with relapsed/refractory non-Hodgkin's lymphoma (NHL) treated with 131I-tositumomab (131I-Tab) or 90Y ibritumomab tiuxetan (90Y-Iab) radioimmunotherapy (RIT). (2006) (0)
Study of Bexarotene , a Retinoic X ReceptorAgonist , in Non-M 3 AcuteMyeloid Leukemia (2008) (0)
Allogeneic cell therapy (act) after relapse from autologous stem cell transplantation (autosct) (2000) (0)
Time from Relapse to Donor Leukocyte Infusion in Allogeneic Stem Cell Transplantation Patients Is Longer for Recipients of Unrelated DLI Compared to Matched Sibling DLI, with Similar Incidence of Graft Versus Host Disease (GVHD) and Survival (2014) (0)
Abstract 4575: Correlates of clinical response following autologous stem cell transplant and adoptive immunotherapy with engineered T cells expressing an affinity-enhanced T cell receptor in patients with mutliple myeloma. (2013) (0)
Higher Donor Apheresis Blood Volumes Are Associated with a Reduction in Relapse Risk and Improved Survival in Reduced Intensity Allogeneic Transplants with Unrelated Donors (2018) (0)
bortezomib- containing regimens cell collection following initial therapy with thalidomide, lenalidomide or Mobilization in myeloma revisited: IMWG consensus perspectives on stem (2009) (0)
315: Similar Survival after Sibling vs Unrelated Donor Allogeneic Stem Cell Transplantation with Reduced Intensity Conditioning (2008) (0)
Multi-Dose Pharmacokinetic Study of Plerixafor in a Morbidly Obese Patient with Multiple Myeloma and Dialysis-Dependent Renal Impairment (2012) (0)
A Phase I Trial of Bexarotene, a Retinoid X Receptor Agonist, in non-M3 Acute Myeloid Leukemia: Evidence of Myeloid Differentiation and Clinical Activity. (2006) (0)
Efficacy a nd S afety o f G emtuzumab O zogamicin i n P atients With C D33-Positive A cute M yeloid L eukemia i n F irst Relapse (2001) (0)
Allogeneic Stem Cell Transplantation in Patients ≥70 Years Old (2016) (0)
Higher Apheresis Blood Volumes Are Associated with a Reduction in Relapse Risk and Improved Survival in Patients Undergoing Reduced Intensity Allogeneic Transplants from Unrelated Donors, Potentially Due to Higher CD8 T-Cell Doses (2016) (0)
Timing between Rituximab and 90 Y-Ibritumomab Tiuxetan in Pts with Non-Hodgkin’s Lymphoma Does Not Affect Clinical Outcomes. (2006) (0)
Unrelated Donors Are Associated with Improved Relapse Free Survival Compared to Related Donors in Patients with Myelodysplastic Syndrome Undergoing Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation (2015) (0)
Impact of Renal Dysfunction Measured By Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT) (2019) (0)
251: Low rates of chimerism occur when alemtuzumab is added to conditioning therapy for non-myeloablative allogeneic stem cell transplantation (2007) (0)
Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations with Prognostic Significance in Chronic Lymphocytic Leukemia (2015) (0)
Reduced Intensity Conditioning with Fludarabine/Busulfan 6.4mg/Kg Results In High Donor Chimerism and Low Toxicity In Both Related and Unrelated Allo-SCT for Hematologic Malignancies. (2010) (0)
Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes (2019) (0)
Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of Stamina Trial (2023) (0)
A phase I trial of bexarotene, a retinoid X receptor agonist, in non-M3 acute myeloid leukemia (2007) (0)
Initial Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase I Clinical Trial of Systemic C-MYB Antisense Oligodeoxynucleotide in Subjects with Refractory Hematologic Malignancies (2008) (0)
B Cell Lymphoma, Unclassifiable: Survival Advantage for Aggressive Therapy (2011) (0)
Fluoroquinolone prophylaxis for the prevention of central line-associated bloodstream infection in autologous stem cell transplant. (2017) (0)
Post Autologous Transplant (autoHCT)Therapies in High Risk MM. Subgroup analysis of Phase III BMTCTN 0702 STAMINA: autoHCT Followed by Lenalidomide Maintenance(Len)(AM) vs auto HCT and Len and Bortezomib (BZ) and Dexamethasone Consolidation Len Maintenance(ACM) vs Tandem autoHCT Len Maintenance (2017) (0)
Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation (Auto HCT) for Multiple Myeloma (MM): An Analysis from the Center for International Blood and Marrow Transplant Research (CIBMTR). (2008) (0)
Clinical Trial of a Multitarget EBV PCR Panel In Patients with EBV Positive Malignancies: Correlation of Peripheral Blood EBV Viral Load with Disease Activity (2010) (0)
APhase I Study of Bexarotene, a Retinoic X ReceptorAgonist, in Non-M3 AcuteMyeloid Leukemia (2008) (0)
Effect of bexarotene on platelet counts in patients undergoing cancer treatment: An analysis of clinical trials in lung cancer and leukemia. (2009) (0)
Infectious complications following Venetoclax-Proteasome Inhibitor based regimens in relapsed myeloma: a single center retrospective analysis (2019) (0)
Allogeneic Hematopoietic Cell Transplantation (HCT) for Neuroblastoma (NB): The CIBMTR Experience (2011) (0)
Letermovir Vs High Dose Valacyclovir for Cytomegalovirus Prophylaxis Following Haploidentical Allogeneic Hematopoietic Transplantation (2021) (0)
Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease. (2009) (0)
DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma (2022) (0)
Blockade of CCR5 to protect the liver graft in HIV/HCV co-infected patients (2013) (0)
History of Autologous SCT Does Not Appear to Blunt the Serologic Response to COVID-19 Vaccination for Patients with Lymphoid Malignancies (2022) (0)
Development of the Renal Adjusted Hematopoietic Cell Transplant Comorbidity Index (RA-HCT-CI) Using Different Levels of Renal Dysfunction According to Estimated Glomerular Filtration Rate (eGFR) (2020) (0)
High CD8 Cell Doses Correlate with Reduced Relapse Risk and Improved Survival after Allogeneic Peripheral Blood Stem-Cell Transplantation with Reduced-Intensity Conditioning (2014) (0)
Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant (2022) (0)
Detection of the Malignant B Cell Clone in Multiple Myeloma Via High Throughput Sequencing Is Robust to Significant Levels of Somatic Hypermutation (2014) (0)
Transfer of inﬂuenza vaccine–primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of inﬂuenza immunity: results of a randomized clinical trial (2010) (0)
Autophagy and mTOR inhibition as mechanisms for combatting chemoresistance to standard chemotherapy: Final results of a phase I study of infusional cyclophosphamide (cy), pulse dexamethasone (dex), rapamycin (rapa) and hydroxychloroquine (HCQ) (2015) (0)
Biologic Assignment Clinical Trials in Hematopoietic Stem Cell Transplantation (HSCT) for Multiple Myeloma: Baseline Characteristics by Treatment Allocation from BMT CTN 0102 According to Availability of an HLA-Matched Sibling Donor. (2007) (0)
Long Term Neurologic Outcomes for Patients Receiving CAR-T Therapy for Non-Hodgkin’s Lymphoma Who Developed Severe Neurotoxicity (2023) (0)
The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302). (2021) (0)
Time from relapse after allogeneic stem cell transplantation (SCT) to donor leukocyte infusion (DLI) is longer, incidence of GVHD is higher, but survival is similar for recipients of unrelated DLI compared to matched sibling DLI. (2011) (0)
Safety and Efficacy From Intravenous Busulfan with PK-Directed Dosed Adjustment and Bortezomib Conditioning Regimen in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation (2013) (0)
A Phase 1 Dose Escalation Study of Infusion of Ex Vivo CD3/CD28 Costimulated Umbilical Cord Blood-Derived T Cells in Adults Undergoing Transplantation for Advanced Hematologic Malignancies (2011) (0)
Characterizing the Incidence of Pneumonitis in Haploidentical Vs. HLA-Matched Allogeneic Hematopoietic Stem Cell Transplants Receiving Total Body Irradiation (2021) (0)
Infectious Complications of B-Cell Maturation Antigen (BCMA)-Targeted Therapies for Relapsed/Refractory Multiple Myeloma (2022) (0)
CAR-T Cellular Therapies for Multiple Myeloma (2015) (0)
Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Non-Malignant Diseases. (2022) (0)
A Study of Outcomes of Diffuse Large B Cell Lymphoma in the Elderly (2011) (0)
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. (2009) (0)
A Phase II Trial of Bexarotene, a Retinoid X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia (2008) (0)
Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. (2020) (0)
A165 Are TBI-Based Conditioning Regimens Better for Obese Patients Receiving Autotransplants for Myeloma? (2009) (0)
Whole Blood Donor Chimerism At Day 30 After Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation Predicts Disease Relapse, and Is Strongly Associated with Pretransplant Lymphodepletion (2011) (0)
Improving outcomes in mantle cell lymphoma patients treated with R-CHOP using autologous transplant. (2012) (0)
Adoptive Cell Therapies: Keeping Pace With New and Emerging Advances (2020) (0)
Schedule Dependent Effects of Adoptively Transferred Autologous T Cells After AutoSCT for Myeloma: Accelerated Immune Recovery Is Associated with Improved Event-Free Survival. (2009) (0)
Abstract A42: Quantification of MYC expression and mTORC signaling as biomarkers of BET inhibition in multiple myeloma. (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Edward A. Stadtmauer?

Edward A. Stadtmauer is affiliated with the following schools:

Medical College of Wisconsin
University of California, San Diego
University of Pennsylvania

Edward A. Stadtmauer's Academic­Influence.com Rankings

Edward A. Stadtmauer's Degrees

Why Is Edward A. Stadtmauer Influential?

Edward A. Stadtmauer's Published Works

Published Works

What Schools Are Affiliated With Edward A. Stadtmauer?

Edward A. Stadtmauer's AcademicInfluence.com Rankings